Results published in The New England Journal of Medicine of the first typhoid conjugate vaccine (TCV) study in Africa, have shown that TCVs work in Malawian children, with an impressive 84 percent efficacy.
The study was conducted by the Typhoid Vaccine Acceleration Consortium (TyVAC) in partnership with the Malawi-Liverpool-Wellcome Trust in Blantyre, Malawi.
It found a strong vaccine safety profile and an estimated 84 percent efficacy in preventing blood culture-confirmed typhoid fever in children 9 months to 12 years of age.
A total of 27,882 children were randomized (1:1) to receive either the TCV or a serogroup, a meningococcal conjugate vaccine and were followed for 18 to 24 months after vaccination.
Those children who had received TCV were 84 peecent less likely to contract typhoid during that time.
Malawi has had more than 6,600 estimated typhoid cases in 2019 and alarming rates of emerging drug-resistant typhoid strains.
This is the first TCV efficacy study ever conducted in an African setting. The findings are consistent with similar randomized controlled studies in Nepal and Bangladesh and a post-introduction impact study in India.
The World Health Organization, WHO prequalified the first TCV in 2018 and a second in late 2020.